Sumgen Biotech

Sumgen Biotech (尚健生物) is an innovative biopharmaceutical company dedicated to the development and commercialization of innovative biologics. Led by Dr. Ming Lv, a renowned scientist and a key member of the National Thousand Talents Program, Sumgen Biotech has established itself as a leader in the field.

With cutting-edge research centers in Hangzhou and Beijing, Sumgen Biotech has built a complete technological chain covering innovative research, clinical translation, and industrial production. The company focuses on areas such as oncology and autoimmune diseases, creating a series of original products with over a hundred patent applications. Sumgen Biotech has achieved significant milestones, with its first class 1 new drug, SG001 (Enlongsubaidan antibody), receiving conditional market authorization.

Additionally, key products like SG301 are undergoing crucial clinical trials, while several strategic global new products are entering clinical stages. Boasting a team of top talent, including academicians and international experts, Sumgen Biotech prioritizes talent development. Recognized by various levels of government and industry, the company has received multiple rounds of investments from renowned venture capital firms.

It has also been recognized as a potential unicorn company in Hangzhou and China. Committed to technical and product innovation, Sumgen Biotech aims to meet unmet clinical needs and develop high-quality Chinese antibodies for patients worldwide